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Abstract: α-Cyclodextrin/poly(ethylene glycol) (α-CD/PEG) polyrotaxane nanoparticles were prepared
via a self-assembly method. Anticancer drug methotrexate (MTX) was loaded in the nanoparticles. The
interaction between MTX and polyrotaxane was investigated. The formation, morphology, drug release and in
vitro anticancer activity of the MTX loaded polyrotaxane nanoparticles were studied. The results show that the
MTX could be eﬃciently absorbed on the nanoparticles, and hydrogen bonds were formed between MTX and
α-CDs. The typical channel-type stacking assembly style of polyrotaxane nanoparticles was changed after MTX
was loaded. The mean diameter of drug loaded polyrotaxane nanoparticles were around 200 nm and the drug
loading content was as high as about 20%. Drug release proﬁles show that most of the loaded MTX was released
within 8 hours and the cumulated release rate was as high as 98%. The blank polyrotaxane nanoparticles were
nontoxicity to cells. The in vitro anticancer activity of the MTX loaded polyrotaxane nanoparticles was higher
than that of free MTX.
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Introduction
Polyrotaxanes have supramolecular architectures
with cyclodextrins (CDs) threaded in poly(ethylene gly-
col) (PEG) chains, they are attractive materials to bio-
materials scientists and chemists [1-5]. As CDs and
PEG have been approved by Food & Drug Administra-
tion (FDA) in pharmaceutical formulations, the poly-
rotaxanes exhibit great potential applications in drug
delivery. The excellent biocompatibility, multiple func-
tionality and speciﬁc self-assembly capabilities are the
advantages of polyrotaxanes as drug carriers.
Drug-carriers conjugate is an important form for
polyrotaxanes to deliver drugs. With the modiﬁcation
of hydroxyl groups on the CDs, anticancer drugs could
be immobilized on polyrotaxanes via cleavable bonds to
form drug-polyrotaxane conjugates [6,7]. The drug re-
lease was triggered by the broken of the cleavable bonds.
High drug loading content was expected to achieve in
the conjugates due to the large amount of hydroxyl
groups. Targeting moieties such as ligands were also
conjugated to polyrotaxanes for multivalent recogniza-
tion. As CDs could slide along and rotate around the
PEG chains, this ﬂexible motion avoided the mismatch
of ligand-receptor interaction. This active recognition
mode was reported as a new strategy to enhance tar-
geting eﬃciency [8,9].
Polyrotaxanes were also fabricated non-viral gene
vectors. Cationic modiﬁed CDs could condense DNA
plasmids eﬃciently [10,11]. The sliding and ro-
tation of CDs along the PEG chains provided a
“live” style to condense DNA. The N/P ratio of the
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DNA/polyrotaxane complex was much lower than that
of the DNA/cationic polymer complex under the same
DNA condensation condition. Stimuli-sensitive bonds
were introduced in the end-caps of polyrotaxane vectors
to control the dissociation of the DNA/polyrotaxane
complex. The released free DNA was favorable to pen-
etrate into nucleu for eﬃcient transfection. The polyro-
taxanes as non-viral gene vectors avoided the over tight
condensation of DNA comparing with other non-viral
vectors such as cationic polymers.
Polyrotaxane nanoparticles were fabricated via
supramolecular self-assembly to deliver anticancer
drugs. Early papers have reported polyrotaxane
nanoparticles as drug carriers, however, the self-
assembly of polyrotaxane nanoparticles were driven by
the crystallization of polyrotaxanes [12-14], whose com-
pact architectures hindered the loading of anticancer
drugs. In our previous work, we reported a new strat-
egy, small π-π conjugated molecules such as coumarin
derivative and cinnamic acid were immobilized on the
terminal groups of PEG chains to prepare amphiphiles
[15,16], α-cyclodextrins (α-CDs) were threaded in the
amphiphiles and the polyrotaxanes self-assembled into
nanoparticles. Anticancer doxorubicin was loaded in
the nanoparticles via hydrophobic group as well as π−π
stacking interactions between drugs and the end-cap
moieties.
Methotrexate (MTX) is an antimetabolite and an-
tifolate drug. It inhibits the metabolism of folic acid
for cancer treatment. Herein, we tried to explore the
loading of MTX in polyrotaxane nanoparticles. The
interaction between MTX and polyrotaxane was inves-
tigated. The formation, morphology, drug release and
in vitro anticancer activity of the MTX loaded polyro-
taxane nanoparticles were studied.
Materials and methods
Materials
PEG (Mn=2000), cinnamic acid and α-CD were
purchased from Aldrich and vacuum dried at
room temperature for 24 h before used. N,N’-
dicyclohexylcarbodiimide (DCC), MTX and DMSO-
d6 were purchased from Aldrich and used as received.
Dulbecco’s modiﬁed Eagle’s medium (DMEM), 100×
mycillin, and fetal bovine serum (FBS) were used to
culture cells for cytotoxicity test. Other chemicals
were purchased from Kelong Chemical Co. (Chengdu,
China) and used without further puriﬁcation.
Measurements
Proton nuclear magnetic resonance (1H NMR) spec-
tra were performed on Brukerav-400 spectrometer with
DMSO-d6 as solvents. Tetramethylsilane (TMS) was
used as the internal reference. Fourier transform in-
frared (FT-IR) spectra were recorded on a Thermo Sci-
entiﬁc Nicolet iS10 spectrophotometer. Ultrasound was
performed on Ultrasonic puriﬁer KQ-300DE, the fre-
quency was at 70%. X-ray diﬀractometry (XRD) pat-
terns were obtained at room temperature on an X’Pert
pro MPD X-ray diﬀractometer, the powder samples
were mounted on a sample holder and scanned from
5◦ to 50◦. Ultraviolet visible (UV-vis) spectra were
recorded on Lambda 650 in a range from 200 nm to
500 nm. Dynamic light scattering (DLS) experiments
were performed on a Malvern ZetasizerNano ZS at an
angle of 90◦ at 25◦C. Transmission electron microscopy
(TEM) was performed on Hitachi H600-4. Atomic
force microscopy (AFM) imaging was performed using
MFP3D (Asylum Research) with tapping mode.
Synthesis of cinnamic acid modiﬁed PEG
20 g of PEG (Mn=2000) and 4.44 g of cinnamic acid
were dissolved in 200 mL of dichloromethane, 7.98 g
of DCC dissolved in 100 mL of dichloromethane was
slowly dripped into the mixture in an ice bath. The
mixture was stirred in dark at room temperature for 24
h after the solution of DCC was dripped over. The in-
soluble N,N-dicyclohexylurea (DCU) was ﬁltered. The
ﬁltrate was concentrated in a rotary evaporator. The
modiﬁed PEG was precipitated in excessive diethyl
ether. The product was ﬁltered and dried in vacuum.
Preparation of polyrotaxanes
1 g of cinnamic acid modiﬁed PEG was dissolved in
20 mL of distilled water, the solution was added to 10
mL of saturated aqueous solution of α-CDs. The mix-
ture was ultrasonically agitated for 10 min and stand at
4◦C overnight to precipitate white paste. The product
was collected by centrifugation, washed with distilled
water three times to remove the unthreaded α-CDs.
The white precipitate was vacuum dried at room tem-
perature to get polyrotaxanes.
Biocompatibility test
HepG2 cells were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) at 37◦C in 5% CO2 atmo-
sphere. HepG2 cells harvested in a logarithmic growth
phase were seeded on 96-well at a cellular density of
1 × 104 cells/well and incubated for 1 day. Polyrotax-
anes were dissolved and diluted in phosphate buﬀer so-
lution (PBS) buﬀer with the concentration ranged from
1 × 10−4 to 1 mg/mL. The polyrotaxanes and HepG2
cells were incubated for 72 h. The CCK-8 assay at 490
nm was performed and the percentage of cell viability
was then determined.
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Preparation of MTX loaded polyrotax-
ane nanoparticles
Polyrotaxane (10 mg) and MTX (5 mg) were dis-
solved in 1 mL of DMSO. The solution was added into
10 mL of distilled water dropwise with vigorous stir-
ring in dark. The solution was transferred to a dialysis
tubing (MWCO=3500) and dialyzed at 4◦C against dis-
tilled water for 48 h. The solution in tubing was freeze-
dried to obtain MTX loaded polyrotaxane nanoparti-
cles.
The MTX loaded polyrotaxane nanoparticles were
dissolved in 3 mL of DMSO to determine the drug load-
ing content. The MTX concentration was tested using
the UV-vis spectrophotometer at 388 nm. The drug
loading content was calculated based on the standard
curve obtained from MTX in DMSO. The drug loading
content (DLC) and encapsulation eﬃciency (EE) were
calculated according to the following formula:
DLC (wt %) = (weight of loaded drug/weight of drug
loaded nanoparticles) × 100%
EE (%) = (weight of loaded drug/weight of drug in
feeding) × 100%
In vitro drug release
The drug loaded polyrotaxane nanoparticles were
dispersed and diluted in PBS solution to get ﬁnal con-
centration of 2 mg/mL. The diluted solution (0.5 mL)
was transferred to dialysis tubing (MWCO=3500). The
tubings were then immersed in a ﬂask containing 25mL
of PBS solution (pH=7.4), shaking at a speed of 100
rev/min at 37◦C. At speciﬁc time intervals, 1mL of so-
lution was withdrawn from the release medium and re-
placed with fresh PBS solution.
In vitro anticancer activity
HepG2 cells at a logarithm phase were seeded on 96-
well culture dish at a cell density of 1×104 cells/well.
After incubated for 1 day, free MTX and MTX loaded
polyrotaxane nanoparticles were dispersed and diluted
in PBS solution with diﬀerent concentrations (from
0.001 to 1 mg/mL) and incubated for 72 h. The cul-
ture medium was removed and the wells were rinsed
with PBS for three times (pH = 7.4). DMEM mediums
containing 10 μL of CCK-8 solution was added to each
well. After the cells were incubated for additional 2 h,
the absorbance was measured in a Thermo Varioskan
Flash microplate reader at the wavelength of 490 nm.
Results and discussion
The schematic illustration of the self-assembly of
the drug loaded polyrotaxane nanoparticles was pre-
sented in Scheme 1. The cinnamic acid modiﬁed PEG
threaded in the cavity of α-CDs to receive polyro-
taxanes. The MTX was loaded in the polyrotaxane
nanoparticles. Two drug loaded polyrotaxane nanopar-
ticles with diﬀerent α-CD concentrations in PEG chains
were prepared.
1H NMR spectrum was used to characterize the for-
mation of polyrotaxane. The protons of CH2CH2O in
PEG chain appeared at δ=3.5 ppm. The assignment of
the protons in α-CDs in the polyrotaxanes was shown
in Fig. 1. The proton signals of the hydroxyl groups
in b-OH and c-OH appeared at δ=5.52 and 5.44 ppm,
respectively. The signal in δ=4.8 ppm was attributed
to the proton in carbon (a) in the α-CD backbone. The
peak at δ=4.48 ppm was assigned to the proton in f-
OH. As the chemical environment of the protons in the



















































Scheme 1 The illustration of the self-assembly of MTX loaded polyrotaxane nanoparticles.
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protons in the α-CD backbone (c, f, e, b and d) were lo-
cated from δ=3.8 to 3.3 ppm, and the signals were split
into multiple peaks. The protons in both PEG and
α-CDs were detected in the spectrum, which revealed
that the cinnamic acid modiﬁed PEG was threaded in
the cavities of α-CDs [15], The mole ratio of EG/CD
was calculated from the integrities of OCH2CH2 in
PEG and CH(Ca) in α-CDs. It was reported that the
maximum ratio of EG/CD in polyrotaxane was 2.0-2.1
[17,18], The calculated EG/CD ratios of the two poly-
rotaxanes were 2.9 and 4.3 when the feeding concen-
trations of α-CDs were 1.45 and 0.73 g/mL (Table 1),
which implied that thought the cinnamic acid modiﬁed
PEG could thread into the cavity of α-CDs, the thread-
























Fig. 1 The 1H NMR spectrum of α-CDs/PEG polyrotax-
ane.













TX/PN-L 0.73 4.3 18.7 43 150
MTX/PN-H 1.45 2.9 20.8 57 140
PN: polyrotaxane nanoparticle.
a The concentration in feeding.
b Calculated from 1H NMR spectra.
c Tested by DLS.
The drug loading contents (DLC), encapsulation ef-
ﬁciencies (EE) and mean diameters of the two drug
loaded polyrotaxane nanoparticles were summarized in
Table 1. The DLC and EE of MTX/PN-H nanopar-
ticles were 20.8% and 57%, respectively, which were
higher than those of MTX/PN-L. These results indi-
cated that the MTX loaded polyrotaxane nanoparti-
cles with high α-CDs concentration (MTX/PN-H) ex-
hibited relatively higher DLC and EE. Interestingly,
the mean diameter of MTX/PN-H nanoparticles was
slightly smaller than that of MTX/PN-L.
In order to explore the interactions between MTX
and polyrotaxane nanoparticles, XRD, UV-vis and FT-
IR spectra of the drug loaded polyrotaxane nanoparti-
cles were measured. XRD is a powerful tool to study
the crystal structure of materials. The XRD spectra
of blank polyrotaxane nanoparticles, MTX and MTX
loaded polyrotaxane nanoparticles were presented in
Fig. 2. In the XRD spectrum of blank polyrotaxane
nanoparticles, a very strong peak at 2θ=19.7◦ was pre-
sented in the diﬀraction patterns. It was the charac-
teristic peak associated with a channel-type crystalline
structure by virtue of the polymeric nature of the guest
molecules [19]. The XRD spectrum demonstrated that
the cinnamate moiety modiﬁed PEG was threaded in
α-CDs to form necklace-like polyrotaxanes, which was
consistent with the result of 1H NMR spectrum. Free
MTX showed strong crystallization capability in the
XRD spectrum. However, in the spectrum of MTX
loaded polyrotaxane nanoparticles, no strong crystal
peaks were observed, it was likely amorphous material,
the weak peaks located in the sites of neither polyro-
taxane nor MTX. It clearly displayed that the loaded
MTX was in amorphous state and it destroyed the crys-
tal structure of polyrotaxane nanoparticles.





Fig. 2 The XRD spectra of blank polyrotaxane nanopar-
ticles, MTX and MTX loaded polyrotaxane nanoparticles.
The MTX loaded polyrotaxane nanoparticles were
dispersed in distilled water to test their UV absorbance
(Fig. 3(a)). The spectra of MTX and blank nanopart-
ciles were used as controls. As the strong absorbance of
water was below 250 nm, the peaks above 250 nm were
the absorbance of materials. There were two peaks in
the UV spectrum of MTX, a strong peak at 302 nm
and a weak shoulder at 350 nm. The UV absorbance
peak of blank polyrotaxane nanoparticles appeared at
around 280 nm. Comparing with the spectra of MTX
loaded polyrotaxane nanoparticles and MTX, it could
be found that all the peaks of MTX had red shifts.
The peak at 302 nm was shifted to 306 nm and the
absorbance at 350 nm was shifted to 378 nm. This
red shift revealed that interactions between MTX and
polyrotaxane nanoparticles were formed. The UV ab-
sorbance of MTX loaded polyrotaxane nanoparticles
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with diﬀerent concentrations were tested, diﬀerence ab-
sorbance strength was observed and no red shift was
found (Fig. 3(b)). It implied that the red shift was
due to the interaction between MTX and polyrotaxane
nanoparticles [20,21].




































Fig. 3 The UV spectra of polyrotaxane nanoparticles, MTX
and MTX loaded polyrotaxane nanoparticles (a); and MTX
loaded polyrotaxane nanoparticles with diﬀerent concentra-
tions (b).
The FT-IR spectra of MTX, polyrotaxane nanoparti-
cles and MTX loaded polyrotaxane nanoparticles were
presented in Fig. 4. Strong vibrations were observed
around 3200 to 3600 cm−1, which were attributed to the
stretching vibration of hydroxyl and amino groups. The
vibration peaks of polyrotaxane nanoparticles, MTX
and MTX loaded polyrotaxane nanoparticles were at
3410, 3439 and 3423 cm−1, respectively. After MTX
was loaded in polyrotaxane nanoparticles, the vibra-
tion of MTX was shifted to low wavenumber region, and
the vibration of hydroxyl in polyrotaxanes was shifted
to higher wavenumber region, which demonstrated the
formation of hydrogen bonding [22].
The morphologies of both blank and MTX loaded
polyrotaxane nanoparticles were studied by AFM, the
images were shown in Fig. 5. In the blank nanoparticle
image, regular spherical nanoparticles were observed,
the nanoparticles dispersed well in the image and the
diameters of the blank PN-H polyrotaxane nanoparti-
cles ranged from 100 to 200 nm. The height of the
blank nanoparticles measured by AFM was around 10
nm. After MTX was loaded, the shape of the nanoparti-
cles was changed, it was no longer spherical but spindle.
The MTX loaded polyrotaxane nanoparticles dispersed
well on the mica substrate, the height of MTX loaded
polyrotaxane nanoparticles was still about 10 nm. The
loading of MTX resulted in the shape change.



















Fig. 4 The FT-IR of blank polyrotaxane nanoparticles,
MTX and MTX loaded polyrotaxane nanoparticles.
Two drug loaded polyrotaxane nanoparticles of
MTX/PN-L and MTX/PN-H were used to investigate
the release proﬁles (Fig. 6). They were similar, most
of the loaded MTX was released within the ﬁrst four
hours, and the cumulated release rates of MTX/PN-
L and MTX/PN-H nanoparticles were as high as 98%
and 96%, respectively. The release of MTX/PN-H
nanoparticles was a little slower than that of MTX/PN-
L nanoparticles. Comparing to other anticancer drug
loaded polymeric nanoparticles reported previously [23-
27], the release of MTX loaded polyrotaxanes nanopar-
ticles was very fast. There were two reasons to ex-
plain this phenomenon, one was that the hydrophilic-
ity of MTX was better than other anticancer drugs
such as doxorubicin and 9-nitro-20(S)-camptothecin,
which resulted faster diﬀusion from the nanoparticles to
themedium. The other reason was that the hydropho-
bic moieties of the polyrotaxane nanoparticles could not
provide enough hydrophobic interaction to encapsulate
the MTX inside the nanoparticles, most of the drug was
absorbed on the surface of polyrotaxane nanoparticles
via Van der Waals’ force and hydrogen bonding inter-
action. Thus, the MTX was released very fast from
the polyrotaxane nanoparticles. In cancer therapy, sus-
taining low dose of anticancer drug was not preferable
for cancer treatment, which could not kill cancer cells
eﬃciently and induced multidrug resistance in cancer
cells. The polyrotaxane nanoparticles could trigger fast
release of MTX, which was potentially favorable for the
cancer treatment.
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Fig. 5 The morphologies of blank polyrotaxane nanoparticles (a) and MTX loaded polyrotaxane nanoparticles (b), the
samples were PN-H and MTX/PN-H.

























Fig. 6 Drug release proﬁles of MTX/PN-L and MTX/PN-
H nanoparticles.
The two blank PN-L and PN-H nanoparticles were
incubated with HepG2 cells to evaluate their cytotoxi-
city. The concentrations of the two nanoparticles were
ranged from 1 × 10−4 to 1 mg/mL. The cell viabili-
ties of HepG2 cells were presented in Fig. 7. All the
cell viability of the samples were higher than 90% even
when the concentration of nanoparticles was as high
as 1 mg/mL, which was much higher than the concen-
tration for anticancer activity study. The cell viability
results revealed that the blank polyrotaxane nanopar-
ticles were non-toxic to HepG2 cells.
The in vitro anticancer activity of MTX loaded PN-
L and PN-H nanoparticles was tested by CCK-8 assay.
The drug loaded polyrotaxane nanoparticles were incu-
bated with HepG2 cells for 72 h to evaluate their in
vitro anticancer activity. The result showed that MTX
loaded PN-L and PN-H nanoparticles killed HepG2

















































Fig. 8 In vitro anticancer activity of MTX loaded PN-L
and PN-H nanoparticles against HepG2 cells, the incubation
time was 72 hours.
cells in a dose-dependent manner. The value of
half maximal (50%) inhibitory concentration (IC50) of
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MTX loaded PN-L and PN-H nanoparticles calculated
from the inhibition cures in Fig. 8 were 6.1 and 5.5
ng/mL, and that of free MTX was 7.0 ng/mL, the lower
IC50 represented better anticancer activity. These re-
sults indicated that the HepG2 cells were more sensitive
to MTX loaded PN-H nanoparticles. The in vitro an-
ticancer activities of the two nanoparticles were higher
than that of free MTX, which implied that the in vitro
anticancer activity of MTX was enhanced after loaded
in polyrotaxane nanoparticles.
Conclusions
α-CD/PEGpolyrotaxane nanoparticles were fabri-
cated to load anticancer drug MTX. The size of drug
loaded nanoparticles was around 150 nm and the drug
loading content was around 20%. The MTX was ab-
sorbed on the polyrotaxane nanoparticles and hydrogen
bonding between MTX and polyrotaxane nanoparticles
was formed. The loaded MTX destroyed the crystal of
polyrotaxanes and the UV absorbance peaks of MTX
loaded polyrotaxane nanoparticles exhibited red shift.
The MTX loaded polyrotaxane nanoparticles were in
spindle shape, which were diﬀerent from regular spher-
ical shape to blank polyrotaxane nanoparticles. The
loaded MTX was rapidly released from polyrotaxane
nanoparticles and the cumulated release rate was as
high as 98% within the ﬁrst four hours. The poly-
rotaxane nanoparticles were non-toxic to HepG2 cells
and the anticancer activity of MTX loaded polyrotax-
ane nanoparticles was better than that of free MTX.
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